Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00832507 · ClinicalTrials.gov registry record · Phase 2
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
NCT00832507 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 162 participants.
The verdict
NCT00832507, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
Study Summary
This Phase 2, randomized, double-blind, placebo-controlled, multicenter, dose-ranging study will compare the efficacy, safety, and tolerability of cicletanine hydrochloride (HCl) to placebo in subjects with PAH. Study drug will be administered alone, or on the background of stable PAH therapy. The study will consist of 3 periods: a screening period, a 12-week placebo-controlled treatment period, and a long-term, blinded extension period.
Interventions
- DRUG Cicletanine
- DRUG Cicletanine Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2009-01 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00832507
The ClinicalTrials.gov registry entry for NCT00832507 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cicletanine is the first listed.
NCT00832507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00832507 about?
NCT00832507 is a clinical study titled "Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)". This Phase 2, randomized, double-blind, placebo-controlled, multicenter, dose-ranging study will compare the efficacy, safety, and tolerability of cicletanine hydrochloride (HCl) to placebo in subjects with PAH. Study drug will be administered alone, or on the background of stable PAH therapy. The s...
What is the current status of trial NCT00832507?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2009-01. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00832507?
The interventions under investigation include: Cicletanine (DRUG), Cicletanine Placebo (DRUG).
Who is sponsoring clinical trial NCT00832507?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.